Stockbroker · United States

LifeSci Capital

Deals
18
M&A
2
Equity raisings
15
Latest
Sep 2026
Compare

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deal size
Custom range

18 of 18 deals

Deals LifeSci Capital advised on, most recent first
Advisers
Sep 2026 ADARx Pharmaceuticals ––IPOBookrunnerAnnounced446.3Biotech+1 J.P. Morgan (lead manager)Morgan Stanley (lead manager)TD Securities (lead manager)UBS (lead manager)Cooley (issuer)Latham & Watkins (lead manager) ADARx Pharmaceuticals IPO
Sep 2026 ADARx Pharmaceuticals ––PlacementPlacement agent to the lead managersAnnounced89.0Biotech+1 J.P. Morgan (lead manager)Morgan Stanley (lead manager)TD Securities (lead manager)UBS (lead manager) ADARx Pharmaceuticals placement
Aug 2026 Amylyx Pharmaceuticals ––Follow-on offeringBookrunnerAnnounced575.2Biotech+1 Goodwin (issuer)Leerink Partners (lead manager)Morgan Stanley (lead manager)Guggenheim Securities (lead manager) Amylyx Pharmaceuticals equity raising
Aug 2026 Werewolf Therapeutics ––PlacementPlacement agent to the lead managersAnnounced150.0Biotech+2 Leerink Partners (lead manager)Piper Sandler (lead manager)Cantor Fitzgerald (lead manager)Wells Fargo Securities (lead manager)Latham & Watkins (lead manager) Werewolf Therapeutics placement
Aug 2026 Attovia Therapeutics ––IPOUnderwriter and bookrunnerListed289.0Biotech+1 Morgan Stanley (lead manager)Leerink Partners (lead manager)Citi (lead manager)RBC Capital Markets (lead manager)Fenwick & West (issuer)Cooley (lead manager) Attovia Therapeutics IPO
Aug 2026 BlossomHill Therapeutics ––IPOUnderwriterListed150.0Biotech+2 J.P. Morgan (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)H.C. Wainwright & Co. (lead manager)Cooley (issuer)Latham & Watkins (lead manager) BlossomHill Therapeutics IPO
Jul 2026 Apnimed ––IPOUnderwriterListed192.0Biotech+1 BofA Securities (lead manager)Evercore (lead manager)Cantor Fitzgerald (lead manager)Goodwin (issuer)Cleary Gottlieb Steen & Hamilton (lead manager) Apnimed IPO
Jul 2026 Caldera Therapeutics ––PlacementPlacement agent to the lead managersAnnounced278.0Biotech+1 Jefferies (lead manager)TD Securities (lead manager)Guggenheim Securities (lead manager)UBS (lead manager)Cooley (lead manager) Caldera Therapeutics placement
Jul 2026 Research Alliance Corporation III ––PlacementPlacement agent to the lead managersAnnounced100.0Biotech+2 Leerink Partners (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)Kirkland & Ellis (lead manager) Research Alliance Corporation III placement
Jul 2026 Jasper Therapeutics ––PlacementPlacement agent to the lead managersAnnounced132.0Biotech+1 Piper Sandler (lead manager) Jasper Therapeutics placement
Jun 2026 JATT II Acquisition Corp ––PlacementPlacement agent to the lead managersAnnounced225.0Biotech+1 Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)Davis Polk (lead manager) JATT II Acquisition Corp placement
Jun 2026 Parabilis Medicines ––IPOBookrunnerListed670.0Biotech+2 Leerink Partners (lead manager)BofA Securities (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)Goodwin (issuer)Covington & Burling (lead manager) Parabilis Medicines IPO
May 2026 Orphai Therapeutics –Quince TherapeuticsAcquisitionFinancial adviser to Quince Therapeutics (acquirer)Completed–Biotech+2 Dorsey & Whitney (buy-side)Cooley (sell-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side) Quince Therapeutics acquisition of Orphai Therapeutics
May 2026 Quince Therapeutics ––PlacementPlacement agent to the lead managersAnnounced115.0Biotech+2 Gibson Dunn (lead manager)EvercoreCantor Fitzgerald Quince Therapeutics placement
Apr 2026 Obsidian Therapeutics ––PlacementPlacement agent to the lead managersCompleted350.0Biotech+2 Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)Mintz (lead manager)GoodwinSidley Austin (issuer) Obsidian Therapeutics placement
Feb 2026 Perspective Therapeutics ––Follow-on offeringBookrunnerAnnounced175.0Radiopharmaceuticals+2 Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager) Perspective Therapeutics equity raising
Jul 2025 Cyabra Strategy –Trailblazer Merger Corporation IMergerFinancial adviserCompleted106.0Cybersecurity+1 Roth Capital Partners (buy-side)Loeb & Loeb (buy-side)Sullivan & Worcester (buy-side)Lowenstein Sandler (sell-side)Goldfarb Gross Seligman (sell-side) Trailblazer Merger Corporation I and Cyabra Strategy merger
Mar 2025 Brainomix –Parkwalk Advisors, Boehringer Ingelheim Venture FundSeries CSupported the funding round to the issuerCompleted17.5Medtech+2 Brainomix Series C

Activity

Deals by year
LifeSci Capital: deals by year2025: 1, 2026 YTD: 16051015202025: 1 M&A120252026 YTD: 1 M&A2026 YTD: 15 Equity raisings162026 YTDM&AEquity raisings

By announcement date; raisings and IPOs by their own date.

Deals by sector
LifeSci Capital: deals by sectorBiotech15Cybersecurity1Medtech1Pharma1

Sector of the business bought or funded.

Deals by size
LifeSci Capital: deals by sizeUnder US$100m2US$100–500m13US$500m–1bn2Undisclosed1

Disclosed value in US dollars.

Most often across the table

Firms advising the other side of the same deals.

Repeat clients

  • ADARx Pharmaceuticals2 deals
  • Quince Therapeutics2 deals

Offices and contact

Contact

From the firm's own website.

Suggest a correction

A missing deal, a wrong role or an office to add. A link to a public source helps.